Triple Negative Breast Cancer Introduction

  • Triple-negative breast cancer (TNBC):
    • Is a term that has historically been applied to cancers that:
      • Lack expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)
  • TNBC:
    • Tends to behave more aggressively than other types of breast cancer
  • Unlike other breast cancer subtypes (ie, ER-positive, HER2-positive subtypes):
    • There are no approved targeted treatments available:
      • Although immunotherapy (in combination with chemotherapy) is available for those with advanced TNBC:
        • That expresses programmed cell death ligand 1 (PD-L1)
    • One definition “triple-negative” to mean cancers that have:
      • Less than 1% expression of ER and PR as determined by immunohistochemistry (IHC), and that are, for HER2, either 0 to 1+ by IHC, or IHC 2+ and fluorescence in situ hybridization (FISH) negative (not amplified), according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines
    • Although the basic principles of diagnosis and management of TNBC are similar to those of breast cancer in general:
      • Many aspects, including risk factors, molecular and pathologic characteristics, natural history, and chemotherapy sensitivity, are unique to TNBC
#Arrangoiz #BreastSurgeon #CancerSurgeon #SurgicalOncologist #Miami #Mexico #BreastCancer #TripleNegativeBreastCancer #MountSinaiMedicalCenter

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s